Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
Cognition Therapeutics received FDA agreement that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and aligned on key aspects of a pivotal Phase 3 trial for Zervimesine. The registrational program is expected to begin in mid-2027, enrolling DLB patients with psychosis symptoms for a nine-month, placebo-controlled study using the neuropsychiatric inventory (NPI) as a primary endpoint.
Key figures
- Drug Name
- Zervimesine (CT1812)
- Phase Of Trial
- Phase 3
- Dosage
- 100 mg once-daily
- Trial duration
- nine months
- Slowed progression
- 89%
- Registrational start
- mid-2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.